Seller record · Telehealth service

Transcend

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 4 of 8 criteria. S3, pharmacy identification: A site-wide notice states that the seller provides no pharmacy services, and no facility is named. The terms, questions, about, contact and treatment surfaces carry it. 3 more criteria also fail; see the table below.

At a glance

TranscendTelehealth service

2/8criteria passed

Price: Not printed before a consultation or sign-up
Sells: prescription tesamorelin programs, semaglutide GLP-1 programs, and 2 more
FDA letters: None on file

Visit Transcend See all eight dispositions

Telehealth service. Passes 2 of 8 criteria. 2 not verified, counting neither way. Recorded against Standard v1.1.

A physician-led hormone and longevity service offering prescription peptide programs beside its own supplements. It describes itself as a management platform that provides no medical or pharmacy services and employs no healthcare providers.

Operating entity No legal entity name is printed in the footer, the about page, the contact page or the refund policy.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Transcend's website
S2	Prescription gating	NOT VERIFIED	Transcend's schedule a consultation page
S3	Pharmacy identification	FAIL	Transcend's FAQ
S4	Compounding disclosure	NOT VERIFIED	Transcend's treatment options page
S5	Analytical documentation	FAIL	Transcend's FAQ
S6	Business address	FAIL	Transcend's contact page
S7	Price disclosure	FAIL	Transcend's tesamorelin page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe homepage states that medical services are provided by licensed clinicians and that treatment decisions follow a clinical evaluation, and it names no individual prescriber.Source: Transcend's website.

S2NOT VERIFIEDThe order path for a prescription peptide did not resolve, because the page the site offers for scheduling a consultation carries no intake form and no further step. The check is open.Source: Transcend's schedule a consultation page.

S3FAILA site-wide notice states that the seller provides no pharmacy services, and no facility is named. The terms, questions, about, contact and treatment surfaces carry it.Source: Transcend's FAQ.

S4NOT VERIFIEDA statement of whether the prescription peptides sold are compounded did not resolve, because the words compounded and compounding appear on none of the nine pages read. The check is open.Source: Transcend's treatment options page.

S5FAILNo certificate, lot number or purity figure appears on the site.Source: Transcend's FAQ.

S6FAILThe site prints no street address. Its contact page offers a form and an email address instead, and footer, about, refund and treatment surfaces add none.Source: Transcend's contact page.

S7FAILNo price appears for any prescription peptide program anywhere on the site, and each program page offers a consultation instead of a figure.Source: Transcend's tesamorelin page.

S8PASSNo FDA warning letter names the storefront, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: prescription tesamorelin programs, semaglutide GLP-1 programs, hormone therapy, supplements.

Other sellers of the same products

Who sells semaglutide Who sells tesamorelin

Visit Transcend

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.